What is Moyamoya disease?
Moyamoya disease is a rare neurological condition characterized by progressive narrowing of major blood vessels in the brain, leading to the formation of small, fragile collateral vessels that appear like a “puff of smoke” on angiography imaging. This chronic cerebrovascular disorder primarily affects children and young adults, causing recurrent strokes and transient ischemic attacks due to inadequate blood flow to the brain. The disease has a prevalence of approximately 0.5-1 per 100,000 people globally, with significantly higher rates observed in East Asian populations, particularly in Japan and Korea. While the exact cause remains partially understood, genetic factors play a crucial role, with mutations in the RNF213 gene identified in many familial cases.
Key statistics
| Global prevalence: | 0.5-1 per 100,000 people |
| East Asian prevalence: | Up to 10 per 100,000 people |
| Peak age of onset: | Bimodal distribution: 5-10 years and 30-40 years |
| Female to male ratio: | Approximately 1.8:1 |
Symptoms
Common symptoms include: recurrent stroke, transient ischemic attacks, headaches, seizures, cognitive decline, weakness or paralysis, speech difficulties, visual disturbances, and behavioral changes.
In children, moyamoya disease typically presents with ischemic symptoms resulting from inadequate blood flow to the brain. These may include sudden weakness on one side of the body, difficulty speaking or understanding language, vision problems, and recurrent headaches. Children often experience transient ischemic attacks (TIAs) that may be triggered by activities that increase oxygen demand, such as crying, hyperventilation, or physical exertion.
Adults with moyamoya disease more commonly present with hemorrhagic complications, including intracerebral hemorrhage and subarachnoid hemorrhage, which can cause sudden severe headaches, nausea, vomiting, and altered consciousness. Progressive cognitive decline may also occur in adults, affecting memory, attention, and executive function.
Seizures can occur in both children and adults, ranging from focal seizures affecting specific brain regions to generalized tonic-clonic seizures. Some patients may experience involuntary movements or chorea, particularly children with bilateral disease.
Causes and risk factors
Moyamoya disease can occur in both sporadic and familial forms. The familial form accounts for approximately 10-15% of cases and follows an autosomal dominant inheritance pattern with incomplete penetrance. Mutations in the RNF213 gene, located on chromosome 17, are found in up to 95% of familial cases in East Asian populations and about 70% of sporadic cases in the same populations. However, RNF213 mutations are much less common in non-Asian populations with moyamoya disease.
The RNF213 gene encodes a protein involved in angiogenesis and vascular development. Mutations in this gene appear to predispose individuals to the characteristic vascular changes seen in moyamoya disease, though additional genetic and environmental factors likely contribute to disease development.
Risk factors include East Asian ethnicity, family history of moyamoya disease, certain genetic syndromes such as Down syndrome and neurofibromatosis type 1, and previous radiation therapy to the head and neck region. Some autoimmune conditions, including thyroid disorders, may also be associated with increased risk.
Prevention
Currently, there are no established methods for preventing moyamoya disease, as it is primarily a genetic condition. However, genetic counseling and testing can be valuable for families with a history of the disease. Individuals with known RNF213 mutations or a family history of moyamoya disease may benefit from regular neurological monitoring and imaging surveillance.
For those diagnosed with moyamoya disease, prevention focuses on reducing stroke risk through lifestyle modifications, including maintaining adequate hydration, avoiding sudden temperature changes, and managing triggers that might precipitate ischemic events. Regular medical follow-up and adherence to prescribed treatments are essential for preventing disease progression and complications.
Carrier frequency for RNF213 mutations varies significantly by population, with higher rates in East Asian populations where the variant allele frequency can reach 1-2% in some regions.
Complications
Without appropriate treatment, moyamoya disease can lead to severe and life-threatening complications. Recurrent strokes can result in progressive neurological deterioration, including permanent weakness, speech difficulties, cognitive impairment, and developmental delays in children. Intellectual disability may occur in pediatric patients who experience multiple ischemic events during critical periods of brain development.
Hemorrhagic complications, more common in adults, can cause sudden neurological deterioration and may be fatal. These include intracerebral hemorrhage, intraventricular hemorrhage, and subarachnoid hemorrhage from rupture of the fragile collateral vessels.
Long-term complications may include epilepsy, movement disorders, psychiatric symptoms including depression and anxiety, and progressive cognitive decline. Some patients develop moyamoya syndrome secondary to other conditions, which may have additional complications related to the underlying disorder.
Diagnosis
Diagnosis of moyamoya disease relies primarily on characteristic findings on cerebral angiography or magnetic resonance angiography (MRA). The hallmark finding is bilateral stenosis or occlusion of the terminal portions of the internal carotid arteries and proximal portions of the anterior and middle cerebral arteries, accompanied by the development of abnormal collateral vessel networks that appear as a “puff of smoke” (moyamoya in Japanese) on angiography.
Digital subtraction angiography (DSA) remains the gold standard for diagnosis, providing detailed visualization of the cerebrovascular anatomy. However, MRA and computed tomography angiography (CTA) are increasingly used as less invasive alternatives for initial evaluation and follow-up monitoring.
Additional imaging studies may include magnetic resonance imaging (MRI) to assess for signs of stroke, ischemia, or hemorrhage, and perfusion studies using single-photon emission computed tomography (SPECT) or perfusion MRI to evaluate cerebral blood flow and vascular reserve.
Genetic testing for RNF213 mutations may be considered, particularly in patients with a family history of moyamoya disease or in East Asian populations where these mutations are more prevalent. However, genetic testing is not required for diagnosis and may not be informative in non-Asian populations.
Treatment
Treatment for moyamoya disease focuses on improving cerebral blood flow and preventing stroke through both medical and surgical interventions. Medical management includes antiplatelet therapy with aspirin to reduce stroke risk, though the evidence for its effectiveness is limited. Calcium channel blockers may be used to improve cerebral circulation, and anticonvulsants are prescribed when seizures occur.
Surgical revascularization is the primary treatment for moyamoya disease and involves creating new pathways for blood flow to the brain. Direct revascularization procedures include superficial temporal artery to middle cerebral artery (STA-MCA) bypass, which directly connects an external vessel to an intracranial vessel.
Indirect revascularization procedures, often preferred in children, include encephaloduroarteriosynangiosis (EDAS), encephalomyosynangiosis (EMS), and pial synangiosis. These procedures involve placing vascular tissues in contact with the brain surface to stimulate the development of new blood vessels over time.
Combined direct and indirect procedures may be used in some patients to optimize revascularization. The choice of surgical approach depends on patient age, disease severity, vessel anatomy, and surgeon expertise.
Prognosis
The prognosis for moyamoya disease varies significantly depending on the age at diagnosis, disease severity, presence of symptoms, and access to appropriate treatment. With timely surgical intervention, many patients experience significant improvement in symptoms and reduction in stroke risk.
Children generally have better outcomes than adults, particularly when treated early before significant neurological damage occurs. Surgical revascularization in pediatric patients can often halt disease progression and allow for normal development and function.
Adult patients, especially those presenting with hemorrhagic complications, may have a more guarded prognosis. However, appropriate surgical treatment can still provide significant benefit in preventing future strokes and improving quality of life.
Long-term studies suggest that patients who undergo successful revascularization surgery have substantially lower rates of future stroke and better functional outcomes compared to those treated medically alone. Early diagnosis and treatment are crucial for optimizing outcomes.
Quality of life
Living with moyamoya disease requires ongoing medical care and lifestyle adjustments to minimize stroke risk and optimize neurological function. Patients should maintain adequate hydration, avoid extreme temperatures, and manage stress levels, as these factors can affect cerebral blood flow.
Regular physical activity is generally encouraged, though high-intensity exercise or activities that cause hyperventilation should be approached cautiously, especially in children. Swimming and contact sports may need to be limited depending on individual circumstances and physician recommendations.
Cognitive rehabilitation and physical therapy may be beneficial for patients who have experienced strokes or other neurological complications. Educational support and accommodations may be necessary for children with moyamoya disease to ensure academic success.
Mental health support is important, as patients and families may experience anxiety about future strokes and disease progression. Support groups and counseling can provide valuable emotional support and coping strategies.
Pregnancy and fertility
Moyamoya disease can pose significant risks during pregnancy due to the hemodynamic changes and increased stroke risk associated with pregnancy and delivery. Women with moyamoya disease require specialized obstetric and neurological care throughout pregnancy.
The increased blood volume and cardiac output during pregnancy may paradoxically improve cerebral perfusion in some patients, but the risks of hemorrhage and ischemic complications remain elevated. Careful monitoring and often cesarean delivery under controlled conditions are recommended.
Genetic counseling is important for patients with familial moyamoya disease or known RNF213 mutations, as there is a risk of passing the condition to offspring. The inheritance pattern and penetrance should be discussed to help inform family planning decisions.
Children
Moyamoya disease in children typically presents with ischemic symptoms rather than hemorrhage. Early recognition and treatment are crucial for preventing developmental delays and intellectual disability. Children may present with stroke-like episodes, often triggered by crying, fever, or hyperventilation.
Educational accommodations may be necessary, including modifications for cognitive impairments, physical limitations, or frequent medical appointments. School nurses and teachers should be informed about the child’s condition and emergency procedures.
Surgical treatment in children often involves indirect revascularization procedures, which take advantage of children’s greater capacity for developing new blood vessels. The timing of surgery should balance the risks of the procedure against the risk of stroke and developmental impact.
When to see a doctor
Immediate medical attention is required for signs of stroke, including sudden weakness or numbness on one side of the body, difficulty speaking or understanding speech, sudden severe headache, vision changes, or loss of consciousness. These symptoms require emergency evaluation and treatment.
Routine medical care should be sought for persistent headaches, recurrent episodes of weakness or speech difficulties, seizures, or gradual cognitive changes. Children who experience recurrent episodes of neurological symptoms, particularly if triggered by activities like crying or physical exertion, should be evaluated promptly.
Regular follow-up with a neurologist or neurosurgeon experienced in moyamoya disease is essential for monitoring disease progression and determining the need for surgical intervention.
Regional context
Limited data is available regarding moyamoya disease prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan) and the broader Eastern Mediterranean area. Given the significantly higher prevalence in East Asian populations, moyamoya disease is likely less common in these regions, though sporadic cases may occur.
Healthcare providers in these regions should maintain awareness of moyamoya disease, particularly when evaluating young patients with unexplained stroke or recurrent neurological symptoms. Genetic testing patterns may differ from those observed in East Asian populations.
The Global Medical Journal invites healthcare professionals and researchers from the Caucasus and Eastern Mediterranean regions to contribute their clinical experiences and epidemiological data regarding moyamoya disease to improve understanding of this condition’s regional characteristics.
Research and clinical trials
Current research focuses on better understanding the genetic mechanisms underlying moyamoya disease, developing new therapeutic targets, and optimizing surgical techniques. Studies are investigating the role of additional genetic factors beyond RNF213 and exploring gene therapy approaches.
Clinical trials are evaluating new medical treatments, including novel antiplatelet agents and neuroprotective medications. Research into biomarkers for disease progression and treatment response is ongoing.
Surgical research focuses on comparing different revascularization techniques and developing minimally invasive approaches. Studies of perfusion imaging techniques aim to improve patient selection for surgery and monitor treatment effectiveness.
Patients and families can find information about current clinical trials through ClinicalTrials.gov, where numerous studies related to moyamoya disease are listed. Participation in research studies can provide access to cutting-edge treatments while contributing to scientific understanding of this rare condition.
Frequently asked questions
Is moyamoya disease hereditary?
Moyamoya disease can be inherited in families (familial form) or occur sporadically. The familial form accounts for about 10-15% of cases and is associated with mutations in the RNF213 gene. However, having a genetic mutation doesn’t guarantee developing the disease due to incomplete penetrance.
Can moyamoya disease be cured?
While there is no cure for moyamoya disease, surgical revascularization procedures can effectively restore blood flow to the brain and significantly reduce stroke risk. Many patients experience substantial improvement in symptoms and quality of life after successful surgery.
How quickly does moyamoya disease progress?
Disease progression varies among individuals. Some patients experience rapid worsening over months, while others may have stable disease for years. Regular monitoring with imaging studies helps track progression and guide treatment decisions.
Can children with moyamoya disease live normal lives?
With appropriate treatment, many children with moyamoya disease can lead relatively normal lives. Early surgical intervention often prevents further neurological damage and allows for normal development, though some activity modifications may be necessary.
What is the difference between moyamoya disease and moyamoya syndrome?
Moyamoya disease refers to the idiopathic form with no identifiable underlying cause, while moyamoya syndrome describes similar vascular changes that occur secondary to other conditions such as radiation exposure, genetic syndromes, or autoimmune disorders.
Support and resources
International Organizations:
- Orphanet (orpha.net) – Comprehensive rare disease database
- National Organization for Rare Disorders (NORD) – rarediseases.org
- European Rare Diseases Organisation (EURORDIS) – eurordis.org
- Global Genes – globalgenes.org
Disease-Specific Organizations:
- Moyamoya Disease Foundation – moyamoya.org
- Children’s Hemiplegia and Stroke Association (CHASA) – chasa.org
- International Alliance for Pediatric Stroke – iapediatricstroke.org
Research and Clinical Resources:
- ClinicalTrials.gov – For current research studies
- National Institute of Neurological Disorders and Stroke (NINDS) – ninds.nih.gov
Related conditions
- Cerebral arteriovenous malformation
- Fibromuscular dysplasia
- Cerebral cavernous malformation
- Primary arteritis of the central nervous system
- Hereditary hemorrhagic telangiectasia
Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, relevant guidelines. Informational only; not medical advice. CC BY 4.0.
Cite this page
GMJ News Desk. “Moyamoya disease.” GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/condition/moyamoya-disease/
Licensed under CC BY 4.0. Free to share with attribution to GMJ News.Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.
Was this article helpful?